Phoenix Biotech Acquisition Corp.
NASDAQ:PBAX
5.85 (USD) • At close February 14, 2024
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
| 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | |
|---|---|---|---|---|---|---|---|---|---|
| Omzet
| 0 | 0 | 0 | 0.255 | 0 | 0 | 0 | 0 | 0 |
| Kosten van de omzet
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Brutowinst
| 0 | 0 | 0 | 0.255 | 0 | 0 | 0 | 0 | 0 |
| Brutowinstmarge
| 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Onderzoek- en ontwikkelingskosten
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Algemene en administratieve kosten
| 0.431 | 1.521 | 0.567 | 1.373 | 0.787 | 0.327 | 0.355 | 0 | 0 |
| Verkoop- en marketingkosten
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Verkoop-, algemene en administratieve kosten
| 0.431 | 1.521 | 0.567 | 1.373 | 0.787 | 0.327 | 0.355 | 0.252 | 0 |
| Overige kosten
| 0.001 | -0.023 | 0.024 | -0.086 | 0.05 | 0.05 | 0.05 | 0 | 0 |
| Bedrijfskosten
| 0.43 | 1.544 | 0.59 | 1.287 | 0.837 | 0.377 | 0.405 | 0.332 | 0 |
| Bedrijfsresultaat
| 0.43 | -1.544 | -0.59 | 0.378 | 0.145 | -0.112 | -377,997 | -0.332 | 0 |
| Bedrijfsresultaat ratio
| 0 | 0 | 0 | 1.483 | 0 | 0 | 0 | 0 | 0 |
| Totaal overige inkomsten en kosten netto
| 0.122 | 0.151 | 0.109 | 1.563 | 0.982 | 0.265 | 0.027 | -0 | 0 |
| Inkomen voor belasting
| -0.308 | -1.393 | -0.482 | 0.276 | 0.145 | -0.112 | -0.378 | -0.332 | 0 |
| Inkomen voor belasting ratio
| 0 | 0 | 0 | 1.083 | 0 | 0 | 0 | 0 | 0 |
| Belastingkosten
| 0.026 | 0.045 | -0.109 | 0.539 | 0.06 | 0.228 | -377,996.622 | -0.017 | 0 |
| Nettowinst
| -0.334 | -1.438 | -0.373 | -0.263 | 0.085 | -0.339 | 377,996.244 | -0.316 | 0 |
| Nettowinstmarge
| 0 | 0 | 0 | -1.031 | 0 | 0 | 0 | 0 | 0 |
| WPA (Winst Per Aandeel)
| -0.053 | -0.21 | -0.055 | -0.011 | 0.004 | -0.015 | 16,448 | 0 | 0 |
| Verwaterde WPA
| -0.053 | -0.21 | -0.055 | -0.011 | 0.004 | -0.015 | 16,448 | 0 | 0 |
| EBITDA
| -0.43 | -1.544 | -0.59 | -3.208 | -1.498 | -0.604 | -0.432 | -0.332 | 0 |
| EBITDA ratio
| 0 | 0 | 0 | -12.59 | 0 | 0 | 0 | 0 | 0 |